The software uses AI to automate measurements and longitudinal tracking of aortic disease on CT scans, aiming to support radiologists in assessment and follow-up.
RapidAI has received US Food and Drug Administration (FDA) clearance of Aortic Management, part of the Rapid Aortic product, a deep clinical AI solution designed to improve the acute assessment and longitudinal management of aortic disease.
Designed to detect more diseases with greater accuracy, this next-generation AI can potentially reduce the cognitive burden for radiologists, inform acute treatment and transfer decisions, and enhance longitudinal patient management, according to a release from the company.
The solution clinical information powered by AI to help clinicians identify more aortic aneurysms, dissections, and other anomalies and automatically generates critical measurements, produces automated 3D reconstructions of the entire aorta, and tracks anatomical changes over time.
Rapid Aortic enables the analysis of all CT scans that include the aorta—including post-treatment and non-contrast studies—to potentially assist clinicians in identifying and tracking pathology from the aortic arch in the chest to the iliacs in the pelvis. It produces guideline-based measurements, including six zonal maximums and eighteen landmark metrics.
“Rapid Aortic represents a significant advancement for aortic patient management,” says Trissa Babrowski, MD, vascular surgeon at the University of Chicago, in a release. “With instant access to every textbook landmark and zonal maximum measurement, advanced visualizations, and robust longitudinal tracking for surveillance, Rapid Aortic empowers physicians to efficiently identify, confidently assess, and diligently monitor every aortic patient within their system.”
Rapid Aortic is fully integrated into the Rapid Edge Cloud, a cloud-based IT platform with on-prem capabilities that ensures continuous service during any disruptions. Additionally, all modules are integrated into Rapid Navigator Pro, the company’s next-generation radiology solution, as well as the Rapid mobile and web applications.
“This clearance reinforces the depth of our deep clinical AI platform and its growing impact across care teams,” says Karim Karti, CEO of RapidAI, in a release. “Rapid Aortic exemplifies how we’re delivering intelligent, workflow-integrated tools that move beyond detection to full patient management. By combining precision, speed, and seamless interoperability, we’re helping health systems improve efficiency, strengthen care coordination, and ultimately enhance outcomes for patients with aortic disease.”
Photo caption: Aortic Management
Photo credit RapidAI
